Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. 1984

P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch

The ability of normal subjects to hydroxylate mephenytoin (100 mg) or debrisoquine (10 mg) after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee. Urinary recovery of 4-hydroxymephenytoin (4-OH-M) and the urinary S:R enantiomeric ratio of mephenytoin measured in an 8-hr urine sample were investigated as phenotypic traits for mephenytoin, and the urinary metabolic ratio of debrisoquine was used to determine the debrisoquine hydroxylase phenotype. Both urinary 4-OH-M and the S:R ratio of mephenytoin discriminated between extensive (EM) and poor (PM) metabolizers of mephenytoin. The frequencies of PMs for mephenytoin and debrisoquine hydroxylation activity were 2.6% and 7.0%. These two defects in oxidative metabolism were not observed in the same subjects, which suggests that 4-hydroxylation of mephenytoin is a new polymorphism independent of that for debrisoquine.

UI MeSH Term Description Entries
D008297 Male Males
D008617 Mephenytoin An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias. Methoin,Methyl Phenetoin,5-Ethyl-3-Methyl-5-Phenylhydantoin,Mefenetoin,Mesantoin,Phenantoin,5 Ethyl 3 Methyl 5 Phenylhydantoin,Phenetoin, Methyl
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006827 Hydantoins Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS. Hydantoin,Imidazolidine-2,4-Diones,Imidazolidine 2,4 Diones

Related Publications

P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
January 1984, European journal of clinical pharmacology,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
April 1985, British journal of clinical pharmacology,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
January 1989, Pharmacology & therapeutics,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
May 1986, American journal of human genetics,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
January 1996, Psychopharmacology bulletin,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
April 1994, Therapeutic drug monitoring,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
February 1993, Pharmacology & toxicology,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
April 2001, Therapeutic drug monitoring,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
January 1984, Clinical pharmacology and therapeutics,
P J Wedlund, and W S Aslanian, and C B McAllister, and G R Wilkinson, and R A Branch
July 1993, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!